PMID: 9651477Jul 4, 1998Paper

Lipid interactions with human antiphospholipid antibody, beta 2-glycoprotein 1, and normal human IgG using the fluorescent probes NBD-PE and DPH

Biochimica Et Biophysica Acta
Daxin TangS S Pierangeli

Abstract

Recurrent venous thrombosis, arterial thrombosis and pregnancy losses are clinical manifestation associated with antiphospholipid antibody (aPL) that recognizes negatively charged phospholipid antigens. Enzyme-linked immunosorbent assays (ELISA) are generally used to determine the presence and specificity of aPL. In this paper, a fluorescence spectroscopy method has been applied, through monitoring the alteration of fluorescence intensity and anisotropy of a fluorophore that was incorporated in liposomes to explore the changes of molecular structure or configuration elicited by the binding aPL with phospholipid antigens. The bilayer surface was markedly ordered by aPL binding as indicated by the surface-sensitive probe NBD-PE. The binding of aPL on the bilayer surface is saturable. The saturation concentration of aPL is 40% (w/w, aPL/lipid) for cardiolipin membranes. The binding of aPL on cardiolipin took place in the absence of beta 2-GP1. The addition of beta 2-GP1 further increased the anisotropy and decreased the intensity of fluorescence. The binding of aPL is predominantly attributed to electrostatic interaction, but the configuration of the acyl chains of phospholipid also plays a role. It is found that the thermal histo...Continue Reading

References

Feb 1, 1992·Lupus·L R SammaritanoA E Gharavi
May 1, 1990·Journal of Clinical Immunology·R A LevyM D Lockshin
Apr 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M BlankY Shoenfeld
Jan 1, 1990·British Journal of Haematology·E N Harris
Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·H P McNeilS A Krilis
Feb 1, 1989·American Journal of Obstetrics and Gynecology·M D LockshinT Qamar
Oct 1, 1987·British Journal of Rheumatology·E N Harris
May 12, 1981·Biochemistry·J W Nichols, R E Pagano
Nov 1, 1995·Clinical and Experimental Immunology·D BorchmanO P Lamba
May 1, 1994·American Journal of Clinical Pathology·E N HarrisD Birch
Sep 1, 1993·British Journal of Haematology·S S PierangeliW L Dean
Oct 1, 1996·Experimental Eye Research·D Borchman, D Tang

❮ Previous
Next ❯

Citations

Mar 9, 2010·Chemical Reviews·Renatus W SinkeldamYitzhak Tor
Jun 26, 2012·Chemistry and Physics of Lipids·Dan QiuXingyuan Ma
Apr 8, 2015·Chemistry and Physics of Lipids·Cisem AltunayarNadide Kazanci
Jan 7, 2009·Eye & Contact Lens·Douglas BorchmanJim Bell
Mar 3, 2020·Biochimica Et Biophysica Acta. Biomembranes·Abeer Aleskndrany, Ipek Sahin
Jun 17, 1998·Experimental Eye Research·D TangR J Cenedella
Jun 22, 2005·Experimental Eye Research·Vahid GramiDouglas Borchman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.